 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...1112131415161718192021...858859» |
- || obicetrapib (TA-8995) / NewAmsterdam Pharma
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: VINCENT: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (clinicaltrials.gov) - Nov 13, 2024
P2, N=30, Recruiting, Sponsor: NewAmsterdam Pharma
Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Mar 2025 --> Oct 2025
- | Ibrance (palbociclib) / Pfizer, Balversa (erdafitinib) / J&J
Trial completion, Trial completion date: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (clinicaltrials.gov) - Nov 13, 2024
P1, N=35, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Dec 2025 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Mar 2025 --> Oct 2025 Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal: CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia. (Pubmed Central) - Nov 13, 2024
Endothelial cell-specific deletion of CDK6 was sufficient to protect HHT mice from AVM pathology. Thus, clinically approved CDK4/6 inhibitors might have the potential to be repurposed for HHT.
- | Lumakras (sotorasib) / Amgen
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Real-World Evaluation of Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization Among Patients with Non-small Cell Lung Cancer in the US Receiving Sotorasib. (Pubmed Central) - Nov 13, 2024
Thus, clinically approved CDK4/6 inhibitors might have the potential to be repurposed for HHT. Patients in the US receiving sotorasib as 2L+ therapy for NSCLC in real-world clinical practice showed high adherence, TTNT comparable to progression-free survival observed in clinical trials, and HCC similar to those immediately prior to treatment demonstrating real-world benefits with no additional impact on healthcare resources with sotorasib.
- | Ibrance (palbociclib) / Pfizer
Journal, Heterogeneity: A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors. (Pubmed Central) - Nov 13, 2024
Patients in the US receiving sotorasib as 2L+ therapy for NSCLC in real-world clinical practice showed high adherence, TTNT comparable to progression-free survival observed in clinical trials, and HCC similar to those immediately prior to treatment demonstrating real-world benefits with no additional impact on healthcare resources with sotorasib. Treating a sensitive luminal BC PDX with the CDK4/6i palbociclib revealed that, despite initial tumor shrinkage, some tumors might eventually regrow under drug treatment..
- | Nplate (romiplostim) / Amgen, Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Journal, Real-world evidence, Real-world: Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI). (Pubmed Central) - Nov 13, 2024
Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.
- | Lumakras (sotorasib) / Amgen, docetaxel / Generic mfg.
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC). (Pubmed Central) - Nov 13, 2024
Our real-world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history. In this real-world comparative analysis of patients with pretreated KRAS G12C-mutated advanced NSCLC, sotorasib monotherapy demonstrated a longer median OS compared to docetaxel monotherapy or combination therapy.
- | Journal: 'Efficacy of biologics in NSAID-ERD: United airways from the nose to the bronchi'. (Pubmed Central) - Nov 13, 2024
Herein we will review the currently available clinical trial and real-world evidence for biologic efficacy and safety patients with NSAID-ERD, discuss the mechanisms of biologic therapy specific to NSAID-ERD, and review evidence regarding the use of biologic therapy versus endoscopic sinus surgery therapy for CRSwNP and NSAID-ERD. We will propose a management approach for choosing biologic therapy or endoscopic sinus surgery with aspirin therapy after desensitization for patients with NSAID-ERD.
- | Preclinical, Journal: Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro. (Pubmed Central) - Nov 13, 2024
This study provides pre-clinical evidence that AKT inhibitors combined with PI3K inhibitors, cisplatin, or vincristine exhibit additive/synergistic anti-MB activity, and lower doses could be used. The latter also applied to one MB line grown as spheroids, further supporting their future potential use.
- | Journal: Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics. (Pubmed Central) - Nov 13, 2024
So far, dupilumab demonstrated greater efficacy in patients with NSAID-ERD than in aspirin-tolerant patients with regard to several clinical outcomes...Additionally, there are conflicting studies as to whether patients on a T2 biologic become desensitized to NSAIDs, as omalizumab proved to restore tolerance to aspirin in only two thirds of patients. This goal of NSAIDs tolerance should be considered as part of disease control future approaches, representing one of many aspects in a patient-centered care approach.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life. (Pubmed Central) - Nov 13, 2024
Our study highlighted more pronounced psychopathological comorbidities in patients in treatment with NON-SPECIFIC therapies in terms of impulsivity, alexithymia, and emotion regulation. Moreover, treatment efficacy overtime was more pronounced and stable over time in the SPECIFIC group, and psychopathological comorbidity did not influence it.
- || Review, Journal: Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers. (Pubmed Central) - Nov 13, 2024
Moreover, treatment efficacy overtime was more pronounced and stable over time in the SPECIFIC group, and psychopathological comorbidity did not influence it. Notably, four leading contenders in this domain, Rigvir
- | Prolia (denosumab) / Amgen
Retrospective data, Journal: Clinicopathologic and prognostic characteristics of tumor budding-like in giant cell tumor of bone. (Pubmed Central) - Nov 13, 2024
Notably, four leading contenders in this domain, Rigvir The current data support the assessment of TBL structures as a reliable prognostic tool in GCTB, potentially aiding in the development of personalized treatment strategies for patients.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR: Erenumab versus topiramate: migraine-related disability, impact and health-related quality of life. (Pubmed Central) - Nov 13, 2024
The current data support the assessment of TBL structures as a reliable prognostic tool in GCTB, potentially aiding in the development of personalized treatment strategies for patients. This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient-reported outcomes versus patients treated with topiramate.
- | Leqvio (inclisiran) / Novartis
Journal: In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme. (Pubmed Central) - Nov 13, 2024
P
It follows an idealized crossover design where each virtual patient is its own control, comparing inclisiran to 1) placebo as adjunct to high-intensity statin therapy with or without ezetimibe, 2) ezetimibe as adjunct to high-intensity statin therapy, 3) evolocumab as adjunct to high-intensity statin therapy and ezetimibe.The co-primary efficacy outcomes are based on time to the first occurrence of any component of 3P-MACE (composite of CV death, nonfatal MI or nonfatal IS) and time to occurrence of CV death over 5 years. The SIRIUS in-silico trial programme will provide early insights regarding a potential effect of inclisiran on MACE in ASCVD patients, several years before the availability of the results from ongoing CV outcomes trials (ORION-4 and VICTORION-2-P).
- | levofloxacin / Generic mfg.
Journal: Evaluating the effect of sodium alginate and sodium carboxymethylcellulose on pulmonary delivery of levofloxacin spray-dried microparticles. (Pubmed Central) - Nov 13, 2024
The selected formulation containing SA has the potential to extend the release duration. However, further enhancements are required to optimize its performance.
- || Review, Journal: Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary. (Pubmed Central) - Nov 13, 2024
In practice, multiple treatments are required to treat HoFH. The sequencing of these should be made on an individualized basis, with consideration made to the benefits of each intervention.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 13, 2024
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The sequencing of these should be made on an individualized basis, with consideration made to the benefits of each intervention. Trial completion date: Sep 2024 --> Sep 2025
- | KUR-501 / Athenex
Enrollment change: GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma (clinicaltrials.gov) - Nov 13, 2024
P1, N=54, Recruiting, Sponsor: Baylor College of Medicine
Trial completion date: Sep 2024 --> Sep 2025 N=36 --> 54
- | Epogen (epoetin alfa) / Amgen
Enrollment open: EpoAid: Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients with Sepsis or Septic Shock: a Randomized Controlled Trial (clinicaltrials.gov) - Nov 13, 2024
P4, N=200, Recruiting, Sponsor: Medical University of Silesia
N=36 --> 54 Not yet recruiting --> Recruiting
- | Nplate (romiplostim) / Amgen
New P2 trial: Romiplostim N01 in Combination Therapy for Initial Treatment of Severe Primary Immune Thrombocytopenia (clinicaltrials.gov) - Nov 12, 2024
P2, N=36, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date: RAIR DTC: A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer (clinicaltrials.gov) - Nov 12, 2024
P2, N=8, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
- ||||| SYHA1813 / CSPC Pharma, Shanghai Inst. of Materia Medica
New P1/2 trial: Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=380, Not yet recruiting, Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2/3 trial: Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) (clinicaltrials.gov) - Nov 12, 2024
P2/3, N=10, Not yet recruiting, Sponsor: Zhongming Qiu
- | Enrollment open: The Sagittarius Trial (clinicaltrials.gov) - Nov 12, 2024
P3, N=700, Recruiting, Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Stivarga (regorafenib) / Bayer
Trial completion, Trial completion date, Trial primary completion date, Metastases: Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma (clinicaltrials.gov) - Nov 12, 2024
P2, N=38, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Nov 2024 | Trial primary completion date: Mar 2025 --> Nov 2024
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: OASIS (EM): Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (clinicaltrials.gov) - Nov 12, 2024
P3, N=456, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Nov 2024 | Trial primary completion date: Mar 2025 --> Nov 2024 Trial completion date: Jun 2027 --> Feb 2027
- | Prolia (denosumab) / Amgen
New trial: A retrospective analysis of the clinical efficacy of denosumab injections in the treatment of postmenopausal osteoporosis (EUDRACT) - Nov 10, 2024
P=N/A, N=500, Not yet recruiting, Sponsor: Xi'an Honghui Hospital of Xi'an Jiaotong University; Xi'an Honghui Hospital of Xi'an Jiaotong University
- | Nplate (romiplostim) / Amgen
New trial: N01 ITP-002: Study on glucocorticoid combined with gamma globulin and Romiplostim N01 in treatment of initial severe ITP (EUDRACT) - Nov 10, 2024
P=N/A, N=36, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
- | Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
New P4 trial, Real-world evidence, Real-world: Switching from Conventional Immunosuppressants to Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (EUDRACT) - Nov 10, 2024
P4, N=80, Not yet recruiting, Sponsor: The Third Affiliated Hospital, Sun Yat-sen University; The Third Affiliated Hospital, Sun Yat-sen University
- | Prolia (denosumab) / Amgen
New P4 trial, Real-world evidence, Real-world: Effectiveness and Safety of Denosumab (Lukexin) in Patients with Rheumatoid Arthritis Who Have Achieved Disease Activity Target and Postmenopausal Osteoporosis: A 1-Year Follow-Up, Multicenter, Prospective, Real-World Study (EUDRACT) - Nov 10, 2024
P4, N=200, Recruiting, Sponsor: Peking University First Hospital; Peking University First Hospital
- | Prolia (denosumab) / Amgen
New P4 trial: A Randomized Controlled Study on Different Frequencies of Denosumab Treatment in Patients with Bone Metastases from Advanced Non-Small Cell Lung Cancer (NSCLC) (EUDRACT) - Nov 10, 2024
P4, N=220, Not yet recruiting, Sponsor: Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
- | Repatha (evolocumab) / Amgen, Astellas
New P4 trial, Real-world evidence, Real-world: SHENNONG : A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular (EUDRACT) - Nov 10, 2024
P4, N=7000, Recruiting, Sponsor: Peking University First Hospital; Peking University First Hospital
- Prolia (denosumab) / Amgen
LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION () - Nov 9, 2024 - Abstract #CTOS2024CTOS_639;
Furthermore, atypical femur and metatarsal fractures are a known complication of denosumab treatment. Therefore, it is essential to exercise caution when considering denosumab as a treatment option and to have a detailed discussion with patients regarding the potential risks, benefits, and other available treatment alternatives before initiating therapy.
- pazopanib / Generic mfg.
SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT () - Nov 9, 2024 - Abstract #CTOS2024CTOS_620;
Based on the morphology, immune profile, and clinical presentation, the patient was diagnosed with UPS originating in the retroperitoneum, with metastases to the bones and lymph nodes. The patient received denosumab and radiation therapy (35 Gy in 5 fractions) to the left femur and second and fifth thoracic vertebrae, followed by 75 mg/m
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION () - Nov 9, 2024 - Abstract #CTOS2024CTOS_544;
Although the response rate of 17% for patients with RMS fell below our established threshold, over one-fourth of the 11 patients with recurrent, fusion-positive disease experienced confirmed objective responses and PFS at 6 months. The use of pegfilgrastim and a modified 21-day schedule was successful in allowing for continued treatment despite myelosuppression.
- Imlygic (talimogene laherparepvec) / Amgen, Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS
TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA NCT # 03886311) () - Nov 9, 2024 - Abstract #CTOS2024CTOS_484;
The use of pegfilgrastim and a modified 21-day schedule was successful in allowing for continued treatment despite myelosuppression. The data indicates that the combination regimen using Talimogene Laherparepvec, Nivolumab and Trabectedin may be more effective than Trabectedin alone (Median PFS 4.1 months) as treatment for previously treated patients with advanced leiomyosarcoma and liposarcoma with manageable toxicity.
- Imlygic (talimogene laherparepvec) / Amgen
INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA () - Nov 9, 2024 - Abstract #CTOS2024CTOS_473;
Furthermore, we have shown that treatment induces a marked increase in immune infiltration, predominantly of CD8+ T cells. Despite low sample size (though concordant with the incidence of disease), we show a 40% pathologic complete response rate which suggests further exploration in a larger study is warranted.
- EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION () - Nov 9, 2024 - Abstract #CTOS2024CTOS_465;
In an initial heterogeneous cohort of sarcoma patients treated with ICI, we found that TE and IKZF1 expression predicted immune infiltrates, correlated with PFS, expression of inflammatory pathways, and increased in tumors which gained immune infiltrates during ICI treatment. In a second cohort from the TCGA, TE and IKZF1 expression again predicted immune infiltrates when controlling for subtype, correlated with inflammatory signaling pathway expression, and with OS.
- Qinlock (ripretinib) / Ono Pharma
TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY () - Nov 9, 2024 - Abstract #CTOS2024CTOS_416;
The presence of iTAS and its changes after ripretinib were associated with tumor response. The combination of iTAS with size or density may aid in the identification of progressive lesions.
- IDRX-42 / IDRx
IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST () - Nov 9, 2024 - Abstract #CTOS2024CTOS_409;
Additionally, IDRX-42 has activity against all tested K11 + secondary/tertiary mutations with the exception of K14 T670I. It should be noted that T670I is an infrequently reported secondary mutation compared to V654A or AL secondary mutations, possibly due to diminished enzymatic activity compared with the parental K11 mutant kinase.
- Stivarga (regorafenib) / Bayer
GASTROINTESTINAL STROMAL TUMOURS GISTS) IN NEUROFIBROMATOSIS TYPE NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY () - Nov 9, 2024 - Abstract #CTOS2024CTOS_407;
In our series, three patients had c-KIT mutations, which could potentially indicate sporadic GISTs occurring coincidentally in the context of NF1. As expected most of the tumours developed in the small intestine, although 11% were of gastric origin.
- EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS () - Nov 9, 2024 - Abstract #CTOS2024CTOS_380;
Other systemic therapies used concurrently with immunotherapy were cabozantinib (n = 6), temozolomide (n = 2), pazopanib (n = 2), palbociclib (n = 2), gemcitabine (n = 1), ivosidenib (n = 1), and carboplatin/paclitaxel (n = 1)... Decline in ctDNA demonstrates correlation with radiographic response to immunotherapy and improved survival and could be a potential early biomarker of therapeutic efficacy in advanced soft tissue sarcomas.
- Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA () - Nov 9, 2024 - Abstract #CTOS2024CTOS_359;
Our analysis revealed that three patients with DDLPS acquired either cyclin D1 or cyclin D2 amplification in progressing samples following treatment with CDK4/6i. Unlike breast cancer, where cyclin E1 amplification is a well-established driver of resistance to CDK4/6i, these findings suggest a potential role for cyclin D amplification in acquired resistance in LPS.
- Prolia (denosumab) / Amgen
TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE () - Nov 9, 2024 - Abstract #CTOS2024CTOS_335;
Unlike breast cancer, where cyclin E1 amplification is a well-established driver of resistance to CDK4/6i, these findings suggest a potential role for cyclin D amplification in acquired resistance in LPS. The interval of long-term treatment of GCTB with denosumab can be monitored by serum TRACP-5b level.
- COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA () - Nov 9, 2024 - Abstract #CTOS2024CTOS_299;
The screening identified 24 compounds with broad activity across CAIX knock-out/down and WT OS cell lines, that require further validation and exploration under hypoxic conditions, which is ongoing. Regorafenib shows enhanced activity against CAIX-inhibited cells, therefore combining a CAIX inhibitor with regorafenib presents a potential therapeutic advance and should be studied in more detail.
- Prolia (denosumab) / Amgen
RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS () - Nov 9, 2024 - Abstract #CTOS2024CTOS_283;
High-dose denosumab is effective and safe in achieving a complete response in GCLJ within 12 months, but there is a significant risk of progression after treatment discontinuation. Therefore, using RANKL-inhibition according to the described protocol is only justified for cases where other treatments have failed, or disease may lead to disfiguring mutilating surgery.
- Prolia (denosumab) / Amgen
CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS () - Nov 9, 2024 - Abstract #CTOS2024CTOS_273;
Percutaneous sclerotherapy alone is successful in 87% of primary ABCs in this series. We recommend extended curettage surgery, in large uncontained defects, pathologic fracture or risk of fracture in high stress high risk zones or cases with partial healing or in cases with rapid progression.
- Ibrance (palbociclib) / Pfizer
PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE (Harbor Ballroom) - Nov 9, 2024 - Abstract #CTOS2024CTOS_191;
- Ibrance (palbociclib) / Pfizer, Zynyz (retifanlimab-dlwr) / Incyte
A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (Harbor Ballroom) - Nov 9, 2024 - Abstract #CTOS2024CTOS_153;